components lecithin , ethyl alcohol , cholesterol and glycerin were commingled in a large volume flask and set aside for compounding ( alternatively , in all of the embodiments where the glutathione ( reduced ) percentage is 8 . 5 , the glutathione ( reduced percentage ) can be lowered to 8 . 25 with 0 . 25 % tocopherol acetate added ). in a separate beaker , water , hydroxy citric acid , glycerin , polysorbate 20 , glutathione were mixed and heated to 50 degrees c . the water mixture was added to the lipid mixture while vigorously mixing with a high speed , high shear homogenizing mixer at 750 - 1500 rpm for 30 minutes . the homogenizer was stopped and the solution was placed on a magnetic plate , covered with parafilm and mixed with a magnetic stir bar until cooled to room temperature . citrus seed extract were added and the solution was placed in appropriate dispenser for ingestion as a liquid or spray dispenser . analysis of the preparation under an optical light microscope with polarized light at 400 × magnification confirmed presence of both multilamellar lipid vesicles ( mlv ) and unilamellar lipid vesicles . the preferred embodiment includes the variations of the amount of glutathione to create less concentrated amounts of glutathione . the methods of manufacture described in keller et al , u . s . pat no . 5 , 891 , 465 are incorporated into this description . a variation of the preferred embodiment of the invention is the addition of edta ( ethylene diamine tetraacetic acid ) 100 mg per ounce to be encapsulated in the liposome along with the glutathione . liposomal glutathione drink or spray 2500 mg per ounce or form suitable for encapsulation or gel a lipid mixture having components lecithin , ethyl alcohol and glycerin were commingled in a large volume flask and set aside for compounding . in a separate beaker , a water mixture having water , glycerin , glutathione were mixed and heated to 50 . degree . c . the water mixture was added to the lipid mixture while vigorously mixing with a high speed , high shear homogenizing mixer at 750 - 1500 rpm for 30 minutes . the homogenizer was stopped and the solution was placed on a magnetic stirring plate , covered with parafilm and mixed with a magnetic stir bar until cooled to room temperature . normally , citrus seed extract would be added . normally , a spoilage retardant such as potassium sorbate or bht would be added . the solution would be placed in appropriate dispenser for ingestion as a liquid or administration as a spray . analysis of the preparation under an optical light microscope with polarized light at 400 × magnification confirmed presence of both multilamellar lipid vesicles ( mlv ) and unilamellar lipid vesicles . the preferred embodiment includes the variations of the amount of glutathione to create less concentrated amounts of glutathione . the methods of manufacture described in keller et al u . s . pat . no . 5 , 891 , 465 are incorporated into this description . embodiment two of the invention includes the incorporation of the fluid liposome ( such as that prepared in example 1a ) into a gelatin based capsule to improve the stability , provide a convenient dosage form , and assist in sustained release characteristics of the liposome . the present embodiment relates to the use of glutathione in the reduced state encapsulated into liposomes or formulated as a preliposome formulation and then put into a capsule . the capsule can be a soft gel capsule capable of tolerating a certain amount of water , a two - piece capsule capable of tolerating a certain amount of water or a two - piece capsule where the liposomes are preformed then dehydrated . the liposome - capsule unit containing biologically encapsulated material can be taken in addition to orally , used for topical unit - of - use application , or other routes of application such as intra - occular , intranasal , rectal , or vaginal . the composition of examples 1 and 2 may be utilized in the encapsulated embodiment of this invention . gelatin capsules have a lower tolerance to water on their interior and exterior . the usual water tolerance for a soft gel capsule is 10 % on the interior . the concentration of water in a liposome formulation can range from 60 - 90 % water . an essential component of the present invention is the formulation of a liposome with a relatively small amount of water , in the range of 5 - 10 %. by making the liposome in a low aqueous system , the liposome is able to encapsulate the biologically active material and the exposure of water to the inside lining of the capsule is limited . the concentration of water should not exceed that of the tolerance of the capsule for which it is intended . the preferred capsule for this invention is one that can tolerate water in the 15 - 20 % range . the method described by keller et al , u . s . pat no . 6 , 726 , 924 are incorporated in this description . components are commingled and liposomes are made using the injection method ( lasic , d ., liposomes , elsevier , 88 - 90 , 1993 ). when liposome mixture cooled down 0 . 7 ml was drawn into a 1 ml insulin syringe and injected into the open - end of a soft gelatin capsule then sealed with tweezers . the resulting capsule contains 10 mg coq10 . filling of gel caps on a large scale is best with the rotary die method or others such as the norton capsule machine . components are commingled and liposomes are made using the injection method ( lasic , d ., liposomes , elsevier , 88 - 90 , 1993 ). when liposome mixture cooled down 0 . 7 ml was drawn into a 1 ml insulin syringe and injected into the open - end of a soft gelatin capsule then sealed with tweezers . the resulting one gram capsule contains 898 iu of vitamin e . large scale manufacturing methods for filling gel caps , such as the rotary die process , are the preferred method for commercial applications . embodiment number three of the present invention includes the creation of liposome suspension using a self - forming , thermodynamically stable liposomes formed upon the adding of a diacylglycerol - peg lipid to an aqueous solution when the lipid has appropriate packing parameters and the adding occurs above the melting temperature of the lipid . the method described by keller et al , u . s . pat . no . 6 , 610 , 322 is incorporated into this description . most , if not all , known liposome suspensions are not thermodynamically stable . instead , the liposomes in known suspensions are kinetically trapped into higher energy states by the energy used in their formation . energy may be provided as heat , sonication , extrusion , or homogenization . since every high - energy state tries to lower its free energy , known liposome formulations experience problems with aggregation , fusion , sedimentation and leakage of liposome associated material . a thermodynamically stable liposome formulation which could avoid some of these problems is therefore desirable . the present embodiment prefers liposome suspensions which are thermodynamically stable at the temperature of formation . the formulation of such suspensions is achieved by employing a composition of lipids having several fundamental properties . first , the lipid composition must have packing parameters which allow the formation of liposomes . second , as part of the head group , the lipid should include polyethyleneglycol ( peg ) or any polymer of similar properties which sterically stabilizes the liposomes in suspension . third , the lipid must have a melting temperature which allows it to be in liquid form when mixed with an aqueous solution . by employing lipid compositions having the desired fundamental properties , little or no energy need be added when mixing the lipid and an aqueous solution to form liposomes . when mixed with water , the lipid molecules disperse and self assemble as the system settles into its natural low free energy state . depending on the lipids used , the lowest free energy state may include small unilamellar vesicle ( suv ) liposomes , multilamellar vesicle ( mlv ) liposomes , or a combination of suvs and mlvs . in one aspect , the invention includes a method of preparing liposomes . the method comprises providing an aqueous solution ; providing a lipid solution , where the solution has a packing parameter measurement of p a ( p a references the surface packing parameter ) between about 0 . 84 and 0 . 88 , a p v ( p v references the volume packing parameter ) between about 0 . 88 and 0 . 93 , ( see , d . d . lasic , liposomes , from physics to applications , elsevier , p . 51 1993 ), and where at least one lipid in the solution includes a polyethyleneglycol ( peg ) chain ; and combining the lipid solution and the aqueous solution . the peg chain preferably has a molecular weight between about 300 daltons and 5000 daltons . kinetic energy , such as shaking or vortexing , may be provided to the lipid solution and the aqueous solution . the lipid solution may comprise a single lipid . the lipid may comprise dioleolylglycerol - peg - 12 , either alone or as one of the lipids in a mixture . the method may further comprise providing an active compound , in this case glutathione ( reduced ); and combining the active compound with the lipid solution and the aqueous solution . a variation of embodiment three is the combination of glutathione ( reduced ) and edta . additional variations of this embodiment of glutathione ( reduced ) and the compounds claimed in this invention , including levodopa , carbidopa , selenium , and edta are described in keller et al , u . s . pat . no . 6 , 610 , 322 . case 1 . mf aged 4 years has been diagnosed with cystic fibrosis and has the characteristic finding of elevated sweat chloride . she experiences frequent respiratory infections requiring antibiotic therapy and has a chronic cough . her mother described her as having decreased energy for play , which restricted her physical activity . mf &# 39 ; s red blood cell level of glutathione was found to be 136 ( normal range 200 - 400 micromole per l .) in december 2004 . oral liposomal glutathione reduced was ingested in an amount that provided 300 mg glutathione per dose , with one dose per day for two weeks . after two weeks ingesting the combination the individual &# 39 ; s glutathione level was found to be 570 micromole per l . during the interval ingesting the oral liposomal glutathione reduced , the individual was noted to have resolved the clinical symptoms of chronic cough , and to have more energy . her mother described her as being able to function normally after taking the oral liposomal glutathione . the dose was adjusted down to 150 mg per dose , once a day , and the glutathione level reduced to 240 micromole per l ., which has been used for a maintenance dose . 23 years old with cf manifesting with severe chronic lung disease , and chronic sinus congestion . her lung function had been unchanged at a very low level for 2 years . baseline rbc gsh was low at 46 micromole per l . after 3 weeks of therapy the rbc gsh was 246 micromole per l . the normal range of rbc gsh is 200 - 400 micromole per l . clinically , the patient noted a decrease in the amount of mucus secretions in both the sinuses and the lungs as well as an improvement in a cough , which had been chronic . gf , an 18 month old girl with gastrointestinal manifestation of cystic fibrosis . in the first 12 months of life her growth pattern was normal with her weight in the 50 th percentile . at the time of initial evaluation the child had fallen to the 25 th percentile for weight . her glutathione blood levels were normal . the child was treated with the ingestion of liposomal glutathione in a dose of 100 mg per thirty pounds twice a day . after three months of ingesting the liposomal glutathione the child &# 39 ; s growth had returned to normal with her weight falling into the 50 - 60 th percentile . dosing recommendation for the preferred embodiment of the invention , as described in example 1 . 1 teaspoon of oral liposomal glutathione reduced contains approximately 440 mg gsh . suggested dose depends on body weight . recommended amounts are for daily use . a preferred application of the invention to parkinson &# 39 ; s disease is to initially observe the response to glutathione therapy using the intravenous infusion of glutathione 1500 mg . one dose of the 1500 mg . glutathione intravenous is administered every 12 to 24 hours for a total of 3 doses and the response to the therapy is observed . if there is a positive indication ( improvement in the individual &# 39 ; s symptoms of parkinson &# 39 ; s disease ) for the continued use of glutathione , the present invention ( liposomal glutathione ) is utilized as an oral method of maintaining improvement of the parkinson &# 39 ; s symptoms . carbidopa / levodopa : each 10 / 100 tablet contains : carbidopa , 10 mg , and levodopa , 100 mg . each 25 / 100 tablets contains : carbidopa , 25 mg , and levodopa , 100 mg . each 25 / 250 tablet contains : carbidopa , 25 mg , and levodopa , 250 mg . each sustained - release tablet contains : carbidopa , 50 mg , and levodopa , 200 mg . pp is 67 - year - old woman with tremor affecting her hands , which is consistent with parkinson &# 39 ; s disease . she relates being affected by the tremor to the point that she has difficulty closing buttons and writing her signature . she was placed on oral liposomal glutathione reduced , 600 mg . twice a week . after three weeks of ingesting the invention , pp was observed to have significant reduction in her tremor . pp was able to fasten her buttons with more ease and was able to write her signature with less shaking . the preferred initial therapy is the administration of 1 . 5 teaspoons liposomal glutathione , which contains approximately 660 mg . of glutathione twice a day for two weeks . if there is clinical improvement during this time , the dose may be reduced to the level that maintains the good response on a continuing basis . if there is no response at two weeks the therapy at the dose of 1 . 5 teaspoons liposomal glutathione , which contains approximately 660 mg . of glutathione twice a day until the conclusion of the time period , or clinical improvement has been achieved . if there is clinical improvement during this time , the dose may be reduced to the level that maintains the good response on a continuing basis . the word “ selenium ” means the chemical element selenium or pharmaceutically acceptable selenium - bearing compounds . because selenium appears to facilitate biochemical cycles involving glutathione , the purpose of selenium is to be sure that sufficient selenium is present . liposomal glutathione drink or spray 2500 mg per ounce or form suitable for encapsulation or gel components lecithin , ethyl alcohol and glycerin were comingled in a large volume flask and set aside for compounding . in a separate beaker , water , hydroxyl citric acid , glycerin , polysorbate 20 , glutathione were mixed and heated to 50 degrees c . the water mixture was added to the lipid mixture while vigorously mixing with a high speed , high shear homogenizing mixer at 750 - 1500 rpm for 30 minutes . the homogenizer was stopped and the solution was placed on a magnetic plate , covered with parafilm and mixed with a magnetic stir bar until cooled to room temperature . normally , citrus seed extract would be added . normally , a spoilage retardant such as potassium sorbate or bht would be added . the solution would be placed in an appropriate dispenser for ingestion as a liquid or administration as a spray . analysis of the preparation under an optical light microscope with polarized light at 400 × magnification confirmed the presence of both multilamellar lipid vesicles ( mlv ) and unilamellar lipid vesicles . the preferred embodiment includes the variations of the amount of glutathione to create less concentrated amounts of glutathione . the methods of manufacture described in keller et al u . s . pat . no . 5 , 891 , 465 are incorporated into this description .
the invention is a composition administrable orally to provide systemic glutathione and a method for providing systemic glutathione by oral administration of glutathione in a liposome encapsulation . the administration of a therapeutically effective amount of oral liposomal glutathione results in improvement of symptoms in disease states related to glutathione deficiency such as parkinson &# 39 ; s disease and cystic fibrosis . compounds enhancing the effect of the liposomal glutathione are contemplated such as selenium , edta , carbidopa , and levodopa .